If you’ve walked past a med-spa or scrolled skincare content lately, you’ve probably seen “exosomes” promoted as the next big thing — an exosome facial after microneedling, exosome injections for thinning hair, serums promising to switch your skin’s repair machinery back on. The marketing is confident and the biology sounds genuinely exciting. So I want to do something the marketing usually skips: separate what’s real, what’s promising, and what the regulators are actually saying. Because on this one, the gap between the hype and the evidence is wide, and a couple of the details matter for your safety.
What exosomes actually are
Exosomes are tiny membrane-bound packages — a type of extracellular vesicle — that cells release to talk to one another [3]. They ferry proteins, lipids, and genetic messengers like RNA between cells, and in the lab they can carry signals that influence inflammation, blood vessel growth, and tissue repair. That’s the appeal: if a cell’s “instructions for healing” can be bottled and delivered, maybe you can prompt skin to make more collagen or nudge a dormant hair follicle back to work.
The two sources you may have seen advertised differ in origin. MSC-derived exosomes come from mesenchymal stem cells — usually harvested from donor tissue like adipose (fat), bone marrow, umbilical cord, or placenta. Platelet-derived exosomes come from platelets, the same cells behind platelet-rich plasma, and carry platelet growth factors. Most of the published clinical work has used MSC-derived (especially adipose-derived) products; platelet-derived exosomes for skin and hair are even less studied clinically. That distinction matters less than you’d think for the bottom line, though — because of where U.S. regulation lands.
The regulatory reality, stated plainly
Here’s the part the ads leave out. There are no FDA-approved exosome products for skin rejuvenation, hair restoration, or any other medical use [1]. When exosomes are used to treat a condition in humans, the FDA regulates them as drugs and biological products, subject to the same premarket review and approval as any new medicine [1]. None has cleared that bar — not one [7].
This isn’t a technicality clinics can sidestep. The FDA has stated that even applying an exosome product topically after microneedling — a very common med-spa combination — is generally treated as administering an unapproved biologic, not as a cosmetic, once therapeutic claims are attached [1]. Marketing exosomes for hair loss is, by definition, a treatment claim for a medical condition. The agency has issued a standing public safety notification and, as of a 2023 regulatory review, had already sent multiple warning letters to exosome manufacturers, with enforcement continuing since [7]. I’m not raising this to scare anyone — I’m raising it because “FDA-approved” and “available at a clinic” are not the same thing, and a lot of patients understandably assume they are.
What the evidence actually shows
Set the regulation aside for a moment and look at the science on its own terms. The honest summary is: early, limited, and promising — in that order.
For hair, a 2023 systematic review found 16 studies, of which 15 were preclinical (cells and animals) and only one was clinical [3]. A more recent 2025 review identified 11 clinical studies, including two small randomized trials, and reported improvements in at least one hair measure across all of them, with some studies describing gains in hair density [4]. For skin, recent reviews of human studies have similarly reported improvements in wrinkles, elasticity, and hydration, and a 2026 meta-analysis pooled the aesthetic trial data [6]. Those are real signals, and I don’t want to wave them away.
But look at what the reviewers themselves conclude, because that’s where the caution lives. A 2026 scoping review in dermatology put it bluntly: despite commercial availability, the clinical landscape and safety of these therapies “remain undefined” [5]. The underlying studies are mostly small, many are retrospective or non-randomized, they use wildly different products from different sources with no standardization, and follow-up is short [3,4,5]. What stands out to me clinically is the mismatch: the marketing speaks in the language of proven results, while the peer-reviewed literature speaks in the language of “encouraging early findings that require better trials.” Both can be true at once, and the second one should govern your decision.
The safety question I find hardest to ignore
The published studies have generally reported few serious side effects [4]. But I’d caution strongly against reading that as “these are safe,” and here’s why the distinction is more than academic.
Research studies use characterized products under some oversight. The jars sold on the open market often aren’t the same thing. Extracellular-vesicle scientists have their own problem: it’s genuinely difficult to verify what’s actually in a given vial — identity, purity, potency, dose [7]. If a manufacturer can’t prove those, a patient isn’t really buying a defined medicine; they’re buying a preparation of unknown contents.
From an infectious-disease standpoint, that’s exactly what worries me most. The FDA’s 2019 safety alert was triggered by serious adverse events — including infections — in patients treated with unapproved exosome products in Nebraska [2]. A biologic injected or applied to broken skin is only as safe as its sterility and manufacturing, and an unregulated product gives you no way to confirm either.
Does MSC-derived versus platelet-derived change the picture?
A little, but not where it counts. Platelet-derived exosomes are sometimes framed as safer because platelets can come from a patient’s own blood. In practice, once you isolate and concentrate exosomes from that blood, you’ve generally moved beyond the “minimal manipulation” that keeps certain autologous procedures outside drug regulation — so the FDA framework still applies, and clinical evidence for platelet-derived products in skin and hair is thinner still. MSC-derived products, especially those from donor umbilical cord, amniotic, or placental tissue, are precisely the ones named in FDA warnings. Neither source is FDA-approved for these uses. The label on the box doesn’t change that.
If you’re thinking about it anyway
I’m not here to make anyone’s decision, and there are legitimate reasons people pursue aesthetic treatments. But if you’re considering exosomes, a few honest questions are worth asking any provider: Is this product FDA-approved for this use? (The accurate answer is no.) Can you show independent data on what’s in it and that it’s sterile? What are the actual studies behind the claims — and are they randomized trials or small case series? A provider who answers those directly is treating you like an adult; one who deflects to testimonials is selling a story.
Bottom line
Exosomes are a genuinely interesting area of regenerative science, and it’s plausible that well-characterized products will eventually earn a real role in dermatology through proper trials and approval. But as of 2026, that hasn’t happened: no exosome product is FDA-approved for skin or hair, the clinical evidence is early and mostly low-quality, and the unregulated marketplace introduces real safety uncertainty — including infection risk — that the studies don’t capture. Promising is fair. Proven is not. I’d let the science catch up to the marketing before spending significant money, or taking on real risk, on the current generation of these products.
Curious about a specific claim you’ve seen advertised, or how a treatment earns FDA approval in the first place? Ask in the comments — please keep it general, and don’t share personal medical details or request individual advice in a public thread.
This article is for general educational purposes and does not replace individualized medical care. If you’re weighing any aesthetic or regenerative treatment, discuss it with a qualified, appropriately licensed clinician who can assess your specific situation.
References
- U.S. Food and Drug Administration. Public Safety Notification on Exosome Products.
- U.S. Food and Drug Administration. Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products. December 6, 2019.
- Gupta AK, Wang T, Rapaport JA. Systematic review of exosome treatment in hair restoration: preliminary evidence, safety, and future directions. J Cosmet Dermatol. 2023;22(9):2424–2433. doi:10.1111/jocd.15869.
- Al Ameer A, et al. Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources. Clin Cosmet Investig Dermatol. 2025;18:2215–2227. doi:10.2147/CCID.S543451.
- Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026.
- Clinical Advances in Exosome-Based Therapies for Aesthetic Medicine: A Systematic Review and Meta-analysis of Human Clinical Trials. Aesthet Surg J. 2026;46(Suppl 1).
- Regulation of exosomes as biologic medicines: regulatory challenges in exosome development and manufacturing. PMC11307316. Link.
